Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0091)
Name
Arachidonic acid
Synonyms
arachidonic acid; 506-32-1; arachidonate; Immunocytophyte; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonsaeure; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid; UNII-27YG812J1I; CCRIS 6312; CHEBI:15843; 27YG812J1I; EINECS 208-033-4; CHEMBL15594; AI3-09613; DTXSID4040420; (5Z,8Z,11Z,14Z)-5,8,11,14-Eikosatetraensaeure; 5Z,8Z,11Z,14Z-icosatetraenoic acid; FA 20:4; ARACHIDONIC ACID (20:4, n-6); (5Z,8Z,11Z,14Z)-Icosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid; C20:4; cis-Delta(5,8,11,14)-eicosatetraenoic acid; [1-14C]Arachidonic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Icosatetraenoic acid; ARACHIDONIC ACID (MART.); ARACHIDONIC ACID [MART.]; (14C)Arachidonic acid; Arachidonic Acid, 99%; Immunocytophyt; Vevodar; 5,8,11,14-Icosatetraenoic Acid; arachidonic-acid; 1adl; 1gnj; 1vyg; MFCD00004417; (14C)-arachidonic acid; Spectrum5_001910; Arachidonic Acid, >97%; D0HD9P; Fatty Acid 20:4 n-6; SCHEMBL16162; BSPBio_001539; MLS001361328; ARACHIDONIC ACID [MI]; AA-[d8]; BML3-B03; GTPL2391; ARACHIDONIC ACID [INCI]; 5,8,11,14-Eicosatetraenoate; DTXCID2020420; BDBM22319; ARACHIDONIC ACID [WHO-DD]; CHEBI:137828; HMS1361M21; HMS1791M21; HMS1989M21; HMS3402M21; HMS3649B05; 5Z,8Z,11Z,14Z-Eicosatetraenoate; Arachidonic acid, >95.0% (GC); 5,8,11,14-Eicosatetraenoic acid, labeled with carbon-14, (all-Z)-; Arachidonic acid, analytical standard; cis-D5,8,11,14-Eicosatetraenoate; LMFA01030001; s6185; AKOS015950830; CCG-214838; DB04557; FS-5880; 5,8,11,14-all-cis-Eicosatetraenoate; all-cis-5,8,11,14-Eicosatetraenoate; ARACHIDONIC ACID (20:4 n-6); IDI1_034009; cis-D5,8,11,14-Eicosatetraenoic acid; NCGC00094608-01; NCGC00094608-02; NCGC00094608-03; NCGC00094608-04; NCGC00094608-05; NCGC00094608-06; (all-Z)-5,8,11,14-Eicosatetraenoate; 93444-49-6; AC-14348; AC-33769; BP-29803; SMR000857374; 5,8,11,14-all-cis-Eicosatetraenoic acid; All-cis-icosa-5,8,11,14-tetraenoic acid; HY-109590; A0781; all-cis-eicosa-5,8,11,14-tetraenoic acid; CS-0032762; 5-cis,8-cis,11-cis,14-cis-Eicosatetraenoate; Arachidonic acid (in Tocrisolvetrade mark100); C00219; W15452; FA(20:4(5Z,8Z,11Z,14Z)); 5-cis,8-cis,11-cis,14-cis-Eicosatetraenoic acid; A929392; Q407699; SR-01000838311; SR-01000838311-2; BRD-K03070961-001-02-8; BRD-K03070961-001-04-4; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoicacid; (5Z,8Z,11Z,14Z)-5,8,11,14-Icosatetraenoic acid #; Arachidonic acid, from non-animal source, >=98.5% (GC); Arachidonic acid, from porcine liver, >=99% (GC), liquid; D18DBC10-379C-4E78-9A50-8B791A2F4E68; Arachidonic acid, from porcine liver, >=85% (capillary GC), liquid; Arachidonic acid, 1.0 mg/mL in ethanol, certified reference material; Arachidonic acid, from porcine liver, BioReagent, suitable for cell culture, >=99% (GC)

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C20H32O2
IUPAC Name
(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid
Canonical SMILES
CCCCCC=CCC=CCC=CCC=CCCCC(=O)O
InChI
InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-
InChIKey
YZXBAPSDXZZRGB-DOFZRALJSA-N
PubChem CID
444899
TTD Drug ID
D0HD9P
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model B16 cells Melanoma Mus musculus CVCL_F936
In Vivo Model
Mice (4-5/group) were injected s.c. in the right back flank with 1 x 106 B16 tumor cells. After 7 to 14 days, tumors formed and were collected for flow cytometry analysis. In some mice, tumor growth was monitored till the end point, and CD8-depleting antibodies (200 ug per mice) were injected one day before tumor injection, followed by 4 consecutive injections every 3 days. In B16 melanoma lung metastatic model, mice were injected i.v. with 2 x 105 B16 cells.

    Click to Show/Hide
Response regulation Arachidonic acid from tumor and TME induce tumor-infiltrating CD8T-cell ferroptosis through CD36. Targeting CD36 and ferroptosis may be an effective strategy to improve the antitumor efficacy of T cell-based immunotherapy in melanoma cell line.
References
Ref 1 CD36-mediated ferroptosis dampens intratumoral CD8(+) Tcell effector function and impairs their antitumor ability. Cell Metab. 2021 May 4;33(5):1001-1012.e5. doi: 10.1016/j.cmet.2021.02.015. Epub 2021 Mar 9.